Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 20 de 30 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]
5.Tiene citas relacionadas
Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease - are we on the right road?. N Engl J Med 2014;370:377-8. [Ref.ID 97062]
6.Tiene citas relacionadas Cita con resumen
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Bejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear R, for the Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33. [Ref.ID 97061]
7.Tiene citas relacionadas Cita con resumen
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Seifert HL, Mohs R, for the Alzheimer's Disease Cooperative Study Steering Committee and the Solanezumab Study Group. Phase 3 of solanezumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21. [Ref.ID 97060]
8. Cita con resumen
Anónimo. Tafamidis. Trop d'incertitudes. Prescrire 2012;32:808-10. [Ref.ID 93969]
9.Enlace a cita originalTiene citas relacionadas
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treament of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012;73:504-17. [Ref.ID 92593]
10.Enlace a cita originalTiene citas relacionadas
Ritter JM. Drugs for Alzheimer's disease. Br J Clin Pharmacol 2012;73:501-3. [Ref.ID 92592]
12.Tiene citas relacionadas
Anónimo. Why do the results of randomised and observational studies differ?. BMJ 2011;343:1128. [Ref.ID 91915]
13. Cita con resumen
Mcque K. Merck & Co's MK-677 fails in Alzheimer's phase II. Scrip 2008;3417/18:28. [Ref.ID 84624]
15. Cita con resumen
Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008;70:1672-7. [Ref.ID 82855]
16.
Sagare A, et al.. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007;13:1029. [Ref.ID 81379]
17.Tiene citas relacionadas
Lachmann HJ, Hawkins PN. Eprodisate in AA amyloidosis. Drs. Lachmann and Hawkins reply. N Engl J Med 2007;357:1154. [Ref.ID 81185]
18.Tiene citas relacionadas
Dember LM, Balshaw R. Eprodisate in AA amyloidosis. Drs. Dember and Balshaw reply. N Engl J Med 2007;357:1153-4. [Ref.ID 81184]
19.Tiene citas relacionadas
Manenti L, Transinda P. Eprodisate in AA amyloidosis. N Engl J Med 2007;357:1153. [Ref.ID 81183]
20.Tiene citas relacionadas
Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis. N Engl J Med 2007;356:2413-5. [Ref.ID 80285]
Seleccionar todas
 
 1 a 20 de 30 siguiente >>